Literature DB >> 20502932

Clinical features of Proteus mirabilis pneumonia.

Niro Okimoto1, Toshikiyo Hayashi, Mitsunori Ishiga, Fumiyo Nanba, Michihiro Kishimoto, Shinichi Yagi, Takeyuki Kurihara, Naoko Asaoka, Sadao Tamada.   

Abstract

In this study, we clinically reviewed 13 patients with Proteus mirabilis pneumonia who were admitted for treatment to Kawasaki Medical School Kawasaki Hospital, Okayama, Japan, between April 2006 and July 2009. Clinical features were retrospectively reviewed. Results showed that: (1) hospital-acquired pneumonia occurred in elderly patients with underlying diseases such as cerebrovascular disease; (2) some patients had complications of urinary tract infection due to P. mirabilis; (3) preadministration of antibacterial agents did not become a risk factor; (4) resistance for levofloxacin (LVFX) was observed; (5) prognosis was comparatively good (effective rate 84.7%).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502932     DOI: 10.1007/s10156-010-0059-3

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

1.  Genotypic and phenotypic profiles of virulence factors and antimicrobial resistance of Proteus mirabilis isolated from chicken carcasses: potential zoonotic risk.

Authors:  Matheus Silva Sanches; Ana Angelita Sampaio Baptista; Marielen de Souza; Maísa Fabiana Menck-Costa; Vanessa Lumi Koga; Renata Katsuko Takayama Kobayashi; Sergio Paulo Dejato Rocha
Journal:  Braz J Microbiol       Date:  2019-05-03       Impact factor: 2.476

2.  Pulmonary Pneumatocele in a Pneumonia Patient Infected with Extended-Spectrum β-Lactamase Producing Proteus mirabilis.

Authors:  Sung Hyeok Ryou; Jong Wook Bae; Hyun Jin Baek; Doo Hyuk Lee; Sang Won Lee; Gyu Ho Choi; Kyu Hyung Han; Se Weon Kim; Hyunbeom Kim; Goohyeon Hong
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-10-01

3.  Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.

Authors:  Josef Yayan; Beniam Ghebremedhin; Kurt Rasche
Journal:  BMC Pharmacol Toxicol       Date:  2016-03-23       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.